Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.
Bottom Line: Treatment-related adverse events occurred in 41% of subjects.Most adverse events were related to infusion site and became more frequent with multiple dosing.These results from a population of healthy volunteers support once/day dosing of tedizolid phosphate 200 mg with both the oral and IV formulations, without the need for dose adjustment when switching administration routes.
Affiliation: Cubist, San Diego, California.Show MeSH
Related in: MedlinePlus
Mentions: The study was conducted in four sequential phases: two studies that assessed the PK of IV tedizolid phosphate at doses ranging from 100–400 mg/day (i.e., a single-ascending dose study followed by a multiple-dose study), an absolute bioavailability study, and a venous tolerability study (Figure1).